SG Americas Securities LLC Acquires 78,627 Shares of Hologic, Inc. $HOLX

SG Americas Securities LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 1,662.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 83,358 shares of the medical equipment provider’s stock after acquiring an additional 78,627 shares during the period. SG Americas Securities LLC’s holdings in Hologic were worth $5,626,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HOLX. Chung Wu Investment Group LLC bought a new stake in shares of Hologic in the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 273 shares during the last quarter. SJS Investment Consulting Inc. raised its holdings in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares during the period. Loomis Sayles & Co. L P bought a new stake in Hologic in the second quarter worth $33,000. Finally, Cromwell Holdings LLC boosted its stake in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 436 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Hologic

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.88% of the stock is currently owned by company insiders.

Hologic Trading Down 0.0%

Shares of HOLX opened at $74.87 on Friday. The firm has a market capitalization of $16.69 billion, a price-to-earnings ratio of 30.19, a PEG ratio of 2.12 and a beta of 0.69. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.34. The company has a 50-day moving average of $74.64 and a 200 day moving average of $69.86.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.01 EPS. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $78.00 price target on shares of Hologic in a report on Wednesday, October 22nd. BNP Paribas Exane lowered shares of Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price objective on the stock. in a research report on Friday, November 21st. Argus boosted their target price on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research note on Friday, October 31st. Four equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Hold” and an average price target of $79.29.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.